A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Completed · Phase 1

Conditions studied: Neoplasms

In brief

This is a study in adults with advanced cancer (solid tumours) in whom previous treatment was not successful. The study tests 2 medicines called BI 1387446 and BI 754091. Both medicines may help the immune system fight cancer. In this study, BI 1387446 is given to humans for the first time. The purpose of this study is to find out the highest dose of BI 1387446 alone and in combination with BI 754091 the participants can tolerate. BI 1387446 is injected directly into the tumour. Participants get BI 1387446 injections every week at the beginning and then every 3 weeks. Some participants get BI 754091 in addition to BI 1387446. BI 754091 is given as an infusion into a vein every 3 weeks. As long as they benefit from treatment and can tolerate it, participants can stay in the study for up to 2 years and 8 months. During this time, they visit the study site regularly. At these visit, doctors record any unwanted effects. The doctors also regularly check participants' health.

Key facts

Study ID: NCT04147234
Run by: Boehringer Ingelheim
People needed: 42
Starts: 2020-08-03
Expected to finish: 2024-03-21
Last updated by the study team: 2025-08-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic malignant solid tumor and indication for treatment
Patient must have exhausted established treatment options known to prolong survival for the malignant disease, or is not eligible for established treatment options.
Medically fit and willing to undergo all mandatory trial procedures.
At least one tumor lesion which is suitable for injection (Screening/initial administration), appropriate for the allocated treatment arm, and measurable.
At least 1 discrete lesion, in addition to the lesion proposed for injection, which is amenable to biopsy and is not located in the brain, mediastinum or pancreas.
Adequate organ function or bone marrow reserve
Further inclusion criteria apply

You may not qualify if…

Any investigational or antitumour treatment (including antibodies targeting Programmed Cell Death-1 (PD1) - or programmed Death-Ligand 1 (PDL1)) within 4 weeks or 5 half-life periods (whichever is shorter) prior to the initial administration of BI 1387446 or BI 754091.
Persistent toxicity from previous treatments (including Immune-related Adverse Events (irAEs)) that has not resolved to ≤ Grade 1, except for alopecia, xerostomia, and immunotherapy related endocrinopathies which may be included if clinically stable on hormone supplements or antidiabetic drugs as per Investigator judgement
History or evidence of active, non-treatment related autoimmune disease, except for endocrinopathies which may be included if clinically stable on hormone supplements or antidiabetic drugs.
History or evidence of pneumonitis related to prior immunotherapy
Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 2 weeks prior to the first dose of BI 1387446 or BI 754091.
The tumor at the projected injection site has a high risk for local complications, e.g. bleeding related to encasement/infiltration of major blood vessels or contact with liver capsule, compression of vital structures in case of swelling of injected lesion, in the opinion of the Investigator.
Active infection requiring systemic therapy at the start of treatment in the trial, including active viral hepatitis infection or active tuberculosis infection.
Cardiac insufficiency New York Heart Association (NYHA) III or IV
Left ventricular ejection fraction < 50% measured by echocardiography or Multigated Acquisition (MUGA) scan
Mean resting corrected QT interval (QTc) >470 msec
Further exclusion criteria apply

Where it is running

The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
Froedtert and The Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Hospital Vall d'Hebron — Barcelona, Spain
CIO Clara Campal — Madrid, Spain
Hospital Clínico de Valencia — Valencia, Spain
The Royal Marsden Hospital, Chelsea — London, United Kingdom
Churchill Hospital — Oxford, United Kingdom
The Royal Marsden Hospital, Sutton — Sutton, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.